Is AVTX or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media prefer AVTX or WHWK?

In the previous week, Avalo Therapeutics had 4 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Avalo Therapeutics' score of 0.74 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SLDB or WHWK?

Solid Biosciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Whitehawk Therapeutics N/A N/A -$20.60M -$1.12 N/A

Is SLDB or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media refer more to SLDB or WHWK?

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Solid Biosciences' score of 0.56 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor WVE or WHWK?

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.10 beat WAVE Life Sciences' score of -0.12 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABUS or WHWK?

In the previous week, Arbutus Biopharma had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Arbutus Biopharma and 2 mentions for Whitehawk Therapeutics. Arbutus Biopharma's average media sentiment score of 1.67 beat Whitehawk Therapeutics' score of 1.10 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Whitehawk Therapeutics (WHWK) Competitors

$4.64 -0.07 (-1.42%)

As of 12:26 PM Eastern

Compare

WHWK vs. AVTX, CVAC, SLDB, WVE, and ABUS

Should you buy Whitehawk Therapeutics stock or one of its competitors? Whitehawk Therapeutics's main competitors and comparable companies include Avalo Therapeutics (AVTX), CureVac (CVAC), Solid Biosciences (SLDB), WAVE Life Sciences (WVE), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Whitehawk Therapeutics' return on equity of -53.89% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 138.50%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 76.61%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Whitehawk Therapeutics has lower revenue, but higher earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	17,188.87	-$78.26M	-$4.37	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

In the previous week, Avalo Therapeutics had 4 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Avalo Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Avalo Therapeutics' score of 0.74 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Avalo Therapeutics and Whitehawk Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to CureVac?

Whitehawk Therapeutics (NASDAQ:WHWK) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 0 mentions for CureVac. Whitehawk Therapeutics' average media sentiment score of 1.10 beat CureVac's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Positive
CureVac	Neutral

Whitehawk Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 76.61%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Whitehawk Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CureVac has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Whitehawk Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Whitehawk Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
CureVac	199.92%	-23.03%	-19.09%

Summary

CureVac beats Whitehawk Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Solid Biosciences presently has a consensus price target of $18.18, suggesting a potential upside of 79.54%. Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 76.61%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Solid Biosciences' score of 0.56 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Whitehawk Therapeutics' return on equity of -53.89% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Solid Biosciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

Solid Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Summary

Whitehawk Therapeutics beats Solid Biosciences on 7 of the 12 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Whitehawk Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.52	-$204.38M	-$1.09	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

WAVE Life Sciences currently has a consensus price target of $22.31, indicating a potential upside of 378.09%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 76.61%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.10 beat WAVE Life Sciences' score of -0.12 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences has a beta of -1.3, meaning that its stock price is 230% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Whitehawk Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Summary

WAVE Life Sciences beats Whitehawk Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 2.44%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 76.61%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

In the previous week, Arbutus Biopharma had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Arbutus Biopharma and 2 mentions for Whitehawk Therapeutics. Arbutus Biopharma's average media sentiment score of 1.67 beat Whitehawk Therapeutics' score of 1.10 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.11	-$33.50M	$0.79	6.49
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to Whitehawk Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Summary

Arbutus Biopharma beats Whitehawk Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$266.23M	$4.02B	$7.26B	$12.90B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-4.17	12.34	273.76	25.42
Price / Sales	N/A	1,373.91	679.75	124.45
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	1.45	16.39	12.91	6.15
Net Income	-$20.60M	-$22.72M	$3.48B	$349.24M
7 Day Performance	-4.66%	-1.39%	-0.18%	-1.39%
1 Month Performance	17.25%	11.08%	6.63%	2.55%
1 Year Performance	156.52%	53.50%	25.25%	15.80%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.1806 of 5 stars	$4.64 -1.4%	$8.20 +76.6%	+158.8%	$266.23M	N/A	N/A	21
AVTX Avalo Therapeutics	3.0072 of 5 stars	$20.05 -2.4%	$45.10 +124.9%	+114.4%	$1.10B	$59K	N/A	40	News Coverage
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
SLDB Solid Biosciences	2.1226 of 5 stars	$10.13 +4.2%	$18.18 +79.5%	+89.3%	$1.04B	N/A	N/A	100
WVE WAVE Life Sciences	2.8619 of 5 stars	$5.16 -1.3%	$22.53 +336.6%	-49.3%	$1.03B	$42.73M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. AVTX, CVAC, SLDB, WVE, and ABUS

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Summary

How does Whitehawk Therapeutics compare to CureVac?

Summary

How does Whitehawk Therapeutics compare to Solid Biosciences?

Summary

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

Summary

How does Whitehawk Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. AVTX, CVAC, SLDB, WVE, and ABUS

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Is AVTX or WHWK more profitable?

Do analysts recommend AVTX or WHWK?

Do insiders and institutionals believe in AVTX or WHWK?

Which has better valuation & earnings, AVTX or WHWK?

Does the media prefer AVTX or WHWK?

Which has more volatility & risk, AVTX or WHWK?

Summary

How does Whitehawk Therapeutics compare to CureVac?

Does the media refer more to WHWK or CVAC?

Do analysts prefer WHWK or CVAC?

Do insiders & institutionals have more ownership in WHWK or CVAC?

Which has preferable valuation & earnings, WHWK or CVAC?

Which has more risk & volatility, WHWK or CVAC?

Is WHWK or CVAC more profitable?

Summary

How does Whitehawk Therapeutics compare to Solid Biosciences?

Do analysts recommend SLDB or WHWK?

Does the media refer more to SLDB or WHWK?

Do institutionals & insiders hold more shares of SLDB or WHWK?

Is SLDB or WHWK more profitable?

Which has stronger valuation & earnings, SLDB or WHWK?

Which has more risk and volatility, SLDB or WHWK?

Summary

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

Which has better valuation & earnings, WVE or WHWK?

Do analysts rate WVE or WHWK?

Do institutionals & insiders have more ownership in WVE or WHWK?

Does the media favor WVE or WHWK?

Which has more volatility and risk, WVE or WHWK?

Is WVE or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to Arbutus Biopharma?

Do analysts rate ABUS or WHWK?

Which has more risk and volatility, ABUS or WHWK?

Does the media favor ABUS or WHWK?

Which has stronger earnings & valuation, ABUS or WHWK?

Do institutionals and insiders believe in ABUS or WHWK?

Is ABUS or WHWK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools